Loading viewer...
investor_presentation
Format: PDF investor_presentation
Nuvalent is a clinical-stage biopharmaceutical company developing targeted therapies for non-small cell lung cancer with parallel lead programs for ROS1+ and ALK+ NSCLC. The presentation outlines the company's OnTarget 2026 operating plan, clinical pipeline including zidesamtinib and other candidates, and cash runway extending into 2027.
investor_presentation
Biolase
Varian Medical Systems Acquisition SIRTeX 2018
investor_presentationinvestor_presentation
10 Pages
Varian Medical Systems, Inc.